Anti-inflammatory treatment with colchicine in stable chronic heart failure: a prospective, randomized study

Area of Science:

• Cardiology
• Pharmacology
• Inflammation Research

Background:

• Chronic heart failure (CHF) is characterized by systemic inflammatory activation.
• Inflammation is recognized as a significant therapeutic target in managing CHF.
• Targeting inflammation may offer a novel strategy for improving outcomes in CHF patients.

Purpose of the Study:

• To evaluate the efficacy of a 6-month colchicine regimen in enhancing the functional status of patients with stable chronic heart failure (CHF).
• To assess the impact of anti-inflammatory therapy on key clinical outcomes and functional markers in CHF.

Main Methods:

• A prospective, randomized study involving patients with stable CHF.
• Participants were assigned to receive either colchicine (0.5 mg twice daily) or a placebo for six months.
• The primary endpoint was defined as at least a one-grade improvement in New York Heart Association (NYHA) class.

Main Results:

• Colchicine significantly reduced C-reactive protein and interleukin-6 levels, indicating effective anti-inflammatory action (p < 0.001).
• No significant difference was observed in the primary endpoint (NYHA class improvement) between the colchicine and placebo groups (14% vs. 11%, p = 0.365).
• Rates of death or hospitalization for heart failure and changes in treadmill exercise time were similar between groups.

Conclusions:

• While colchicine effectively reduced inflammatory biomarkers in stable CHF patients, it did not lead to significant improvements in functional status (NYHA class, exercise tolerance).
• The study did not demonstrate a significant impact of colchicine on the composite endpoint of death or heart failure hospitalization.
• Anti-inflammatory treatment with colchicine may not be sufficient to alter clinical outcomes in stable CHF, despite its effects on inflammation markers.